Even though NRP1 is still a promising target for combination regimens with conventional cancer treatments including bevacizumab, the overlapping sets of adverse effects have become the main obstacle to the development of NRP1-targeted drugs [22,23]. The gene discussed is NRP1; the disease is cancer.